Publication
AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer.
Wenlong Wan, Fang Wei, Lu Yang, Xiao Yu, Ziqi Wang, Jianping Miao, Ben Zhao
Biochemical pharmacologySep 18, 2026PMID 42759897doi:10.1016/j.bcp.2026.118486 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260926-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Given the persistently poor five-year survival rate (<10 %) in metastatic bladder cancer (BLCA) and the limited efficacy of conventional chemotherapy and programmed cell death protein 1 (PD-1) inhibitor monotherapy, there is an urgent need to identify novel immune targets and rational combination…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Bladder Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.